Start Time: 08:30 January 1, 0000 9:08 AM ET

Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Q2 2023 Earnings Conference Call

August 03, 2023, 08:30 AM ET

Company Participants

Al Sandrock - President and CEO

Pete Pfreundschuh - CFO

Todd Carter - Chief Scientific Officer

Conference Call Participants

Joon Lee - Truist Securities

Ingrid Ibarra - Wedbush

Jack Allen - Baird

Philip Nadeau - TD Cowen

Matthew Hershenhorn - Oppenheimer

Ross Fladeland - Canaccord Genuity

Operator

Good morning and welcome to Voyager Therapeutics Second Quarter 2023 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request. A replay of today’s call will be available on the Investor section of the company’s website approximately two hours after completion of this call.

I would now like to turn the call over to Pete Pfreundschuh, Chief Financial Officer. Please go ahead.

Pete Pfreundschuh

Thank you and good morning. Joining me on the call today are Dr. Al Sandrock, our Chief Executive Officer; Dr. Todd Carter, our Chief Scientific Officer. We issued our Q2 2023 financial results press release this morning. The press release and the 10-Q are available on our website.

In a moment, I will turn the call over to Al. Before I do this, I want to remind everyone that during this call, Voyager representatives may make forward-looking statements, as noted in Slide 2 of today's deck. These forward-looking statements include future expectations, plans and prospects. All forward-looking statements are inherently uncertain and subject to risks and uncertainties that may cause actual results to differ materially from those indicated by these forward-looking statements. You are encouraged to review and understand the various material risks and uncertainties facing the company as described in the company's most recent annual report on Form 10-K filed with the SEC. As of the filing of today's quarterly report on Form 10-Q, there have been no material changes to the risk factors described in our annual report. All SEC filings are available on the company's website.

Now, it is my pleasure to turn the call over to Al.

Al Sandrock

Thank you, Pete, and good morning, everyone. Please turn to Slide 3. I'd like to start by recognizing the incredible innovation happening right now in neurotherapeutics and in gene therapy. I talked about this on our last call. And since then, we continue to see tremendous progress. On the neurotherapeutics front, just last month, lecanemab received full FDA approval for Alzheimer's disease as well as Medicare coverage. This follows other recent FDA approvals in the neurotherapeutics space, including approvals of medicines for Friedreich's ataxia and amyotrophic lateral sclerosis.